Capsugel launches dosage form solutions division
Will focus on lipid-based formulations
Capsugel has established a Dosage Form Solutions (DFS) business unit to meet growing demand for innovative product development and commercial manufacturing in the healthcare industry.
The DFS business unit, based at the company’s headquarters in Morristown, New Jersey, will focus on lipid-based formulations, while continuing to expand its offerings in targeted release capsules.
‘With the launch of the new DFS business unit, Capsugel builds on its heritage of delivering innovative, quality products and services in hard capsules, by advancing our expertise in product formulation and commercial finished product manufacturing,’ said Guido Driesen, President and CEO of Capsugel. ‘DFS is well-positioned to help address our customers’ most pressing dosage form challenges for existing and new nutritional and pharmaceutical products.’
Amit Patel, who has been appointed as President of the DFS division, said: ‘Continuing to innovate and develop cutting-edge healthcare products is essential to maximising the potential of the industry.’
He added: ‘The DFS business unit uses our proprietary technology platforms to help bring improved products to the market faster for our customers. The platforms can enable various solid oral dosage product improvements including bioavailability enhancement, optimal dosing for potent APIs, controlled release, stability improvement and taste masking.’